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Abstract
Dendritic cells (DCs) play a key role in initiating immune responses and maintaining immune tolerance. In addition
to playing a role in thymic selection, DCs play an active role in tolerance under steady state conditions through
several mechanisms which are dependent on IL-10, TGF-b, retinoic acid, indoleamine-2,3,-dioxygenase along with
vitamin D. Several of these mechanisms are employed by DCs in induction of regulatory T cells which are
comprised of Tr1 regulatory T cells, natural and inducible foxp3
+ regulatory T cells, Th3 regulatory T cells and
double negative regulatory T cells. It appears that certain DC subsets are highly specialized in inducing regulatory T
cell differentiation and in some tissues the local microenvironment plays a role in driving DCs towards a
tolerogenic response. In this review we discuss the recent advances in our understanding of the mechanisms
underlying DC driven regulatory T cell induction.
Introduction
Dendritic cells (DCs) are professional antigen presenting
cells and are essential mediators of immunity and toler-
ance. DCs are the key players in maintaining immune
tolerance, for their ablation has been shown to result in
autoimmunity, highlighting the active role that DCs play
under steady state conditions in maintaining immune
tolerance [1]. In order to prevent autoimmune reactions,
self reactive lymphocytes need to be deleted or their
function needs to be suppressed. The generation of nor-
mal lymphocyte repertoire which is largely self-tolerant
depends on positive and negative selection, which
occurs in the thymus and the process, is referred to as
central tolerance. However, some self-reactive lympho-
cytes that escape thymic deletion enter peripheral tissues
and the suppression of their function is needed to pre-
vent autoimmune reactions, which is referred to as per-
ipheral tolerance. Central tolerance in the thymus is
largely mediated by cortical epithelial cells, medullary
epithelial cells and thymic DCs and involves deletion of
self reactive thymocytes along with induction of natu-
rally occurring regulatory T cells (Tregs), which play a
key role in maintaining self tolerance and suppressing a
variety of pathological immune responses [2]. In
contrast to central tolerance, peripheral tolerance is
mediated by DCs through generation of Tregs and clo-
nal deletion of self reactive T cells. Tregs generated in
the periphery are thought to be important in controlling
immune response to non-self antigens. Peripheral Tregs
include IL-10 secreting Tr1 Tregs, inducible foxp3
+
Tregs, Th3 cells and double negative Tregs. DC induced
generation of these Treg subsets is largely mediated by
IL-27, TGF-b, IL-10, retinoic acid, indoleamine-2,3-diox-
ygenase and vitamin D. The generation of these Tregs is
either mediated by tissue resident specific DC subsets
with a specialized Treg inducing function or by the
action of mediators present in local tissue microenviron-
ment, which act on DCs and drive them to behave as
tolerogenic DCs and induce Treg differentiation. In this
review we provide an overview of the different mechan-
isms employed by DCs in generation of Tregs.
Type 1 regulatory cells
Type 1 regulatory T cells (Tr1) cells are a group of
Tregs characterized by production of IL-10. Although
initial studies pointed towards a central role of IL-10 in
mediating Tr1 generation, recent studies indicate that
Tr1 generation could also be dependent on IL-27. Both
IL-10 and IL-27 are produced by DCs. Aryl hydrocarbon
receptor (AhR), which is a ligand-activated transcription
factor belonging to the basic helix-loop-helix-PER-
ARNT-SIM family, is induced in Tr1 cells and during
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transcription factor belonging to the family of basic
region leucine zipper domain transcription factors and
activates IL-10 and IL-21 promoters [3,4]. Studies to
date have pointed towards a role of DC derived IL-27,
IL-10, TGF-b1 along with a role of ICOSL signalling by
DCs in induction of Tr1 cells. Figure 1 provides an
overview of the pathways involved in DC mediated Tr1
differentiation.
IL-27 production by DCs drives Tr1 differentiation
DCs cultured with Foxp3
+ Tregs secrete elevated levels
of IL-10, IL-27 and TGF-b1, among which TGF- b1 and
IL-27 are important for driving differentiation of Tr1
cells [5]. IL-27 suppresses production of Th17 polarizing
cytokines IL-1b,I L - 6a n dI L - 2 3f r o mD C sa n da c t so n
naive T cells to drive expression of the transcription fac-
tor c-maf, IL-21 and ICOS, which collectively drive dif-
ferentiation of Tr1 cells [6,7]. Furthermore, IL-27
production by DCs also drives IL-10 transcription in T
cells by activation of STAT1 and STAT3, which are
recruited to the IL-10 promoter, further promoting
differentiation of Tr1 cells [8]. Recently, IFN-g has also
been identified to promote DC induced Tr1 generation.
Studies have shown that IFN-g inhibits Th17 inducing
osteoprotegerin (OPG) in DCs and instead promotes IL-
27, which drives induction of Tr1 cells [7,9]. Hepatic
DCs preferentially secrete IL-27 instead of IL-12 upon
LPS stimulation, indicating that hepatic DCs may also
act as inducers of Tr1 cells [10].
IL-10 production by DCs drives Tr1 differentiation
Differentiation of DCs from bone marrow in the pre-
sence of IL-10 leads to generation of a
CD11c
lowCD45RB
high DC subset with a plasmacytoid
morphology and an immature phenotype [11]. These
DCs secrete high amounts of IL-10 upon stimulation
and drive differentiation of naive T cells into IL-10
secreting Tr1 cells. Similarly, skin derived langerhans
cells have also been shown to produce IL-10 which can
also contribute towards generation of Tr1 cells [12].
Similar to murine Tr1 cells, DCs secreting IL-10 also
drives differentiation of human Tr1 cells, which is
dependent on human leukocyte antigen (HLA)-G and
#$ 4 CELL
!H2 C
MAF ),

),
 !H2 C
MAF
),

),
B
),

),

),

/0'
)&.
G
),

0$,

0$

),

)#/3,
)#/3
6)0
"ACTERIAL PEPTIDES
),
 INDUCING 
SIGNALS
4'&
B
4'&
B INDUCING 
SIGNALS
4'&
B
$ENDRITIC #ELL
Figure 1 DCs drive differentiation of Tr1 regulatory T cells. DCs secrete IL-27, IL-10 and TGF-b1, which induce AhR and c-maf in T cells. AhR
and c-maf physically associate with each other and activate IL-10 and IL-21 promoters, driving Tr1 differentiation. IL-27 suppresses production of
Th17 inducing cytokines such as IL-1b, IL-6 and IL-23 and drives Tr1 differentiation. IFN-g suppresses Th17 inducing osteoprotegerin (OPG) and
drives IL-27 production, thereby promoting Tr1 differentiation. Furthermore, PD-1/PDL-1 signaling and bacterial peptides along with vasoactive
intestinal peptide (VIP) drive IL-10 production which also induces Tr1 differentiation. Moreover, ICOS/ICOSL signalling as well as TGF-b production
by DCs has also been implicated in driving Tr1 differentiation.
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is a non classical MHC I molecule, plays a central role
in maintaining fetal-maternal tolerance during preg-
nancy and is expressed on IL-10 producing tolerogenic
human DCs [14]. HLA-G binds to inhibitory immuno-
globulin like transcript (ILT)-2 and ILT-4 receptors
which has been shown to suppress DC maturation
[15,16]. IL-10 produced by DCs acts in a positive feed-
back manner, sustaining HLA-G and ILT4 expression
on DCs along with an induction of HLA-G expression
on T cells. ILT4 on tolerogenic DCs interacts with
HLA-G on T cells and HLA-G on DCs interacts with
ILT2 on T cells, which drives differentiation of T cells
into IL-10 producing Tr1 cells [17]. Monocyte derived
human DCs cultured in presence of 1a,25-dihydroxyvi-
tamin D3 (VD3) show a semi-mature phenotype charac-
terized by low levels of MHC Class II and costimulatory
molecule expression along with production of IL-10 and
impairment of IL-12 production, driving Tr1 differentia-
tion. Moreover, DCs cultured with VD3 upregulate pro-
grammed death ligand -1 (PDL-1) upon activation,
inhibition of which suppresses Tr1 differentiation [18].
PDL-1 signalling on DCs likely promotes IL-10 produc-
tion, since triggering PDL-1 on DCs by soluble PD-1
has been shown to suppress DC maturation and pro-
mote IL-10 production [19]. Altogether, these studies
indicate that VD3 treatment of DCs drives PDL-1 upre-
gulation which acts as an inducer of IL-10 production
by DCs, thereby driving Tr1 differentiation. However, it
remains to be investigated whether HLA-G and ILT4/
ILT2 signalling is involved in VD3 driven induction of
Tr1 cells.
Repetitive stimulation of peripheral CD4
+ T cells by
immature allogeneic DCs can also drive Tr1 generation
[20]. T cells cultured under stimulation by immature
DCs selectively upregulate cytotoxic T-lymphocyte anti-
gen 4 (CTLA4) and lose their ability to produce IFN-g,
IL-2, IL-4 and subsequently differentiate into Tr1 cells
[21]. This is dependent on the ability of immature DCs
to secrete IL-10, which is severely diminished as DCs
undergo maturation. IL-10 production by pulmonary
D C sa l s oa p p e a r st ob ec r i t i c a lf o ri n d u c t i o no fT r 1
induced tolerance. Pulmonary DCs in mice exposed to
respiratory antigens undergo maturation but secrete IL-
10 which drives induction of Tr1 cells. Moreover, these
Tr1 cells can suppress airway responsiveness and their
development is dependent on IL-10 production by DCs,
since adoptive transfer of DCs from IL-10 deficient mice
fail to induce Tr1 mediated tolerance [22]. In a model
of food induced anaphylaxis, tolerance induction is
mediated by gastrointestinal lamina propria DCs,
whereby sugar modified antigens are targeted to C-type
lectin receptor SIGNR-1, resulting in preferential pro-
duction of IL-10 but not IL-6 or IL-12 p70 by DCs,
which ends up driving differentiation of naive T cells
into Tr1 cells [23].
Several strategies that can induce DC production of
IL-10 and prevent maturation have been employed for
generation of Tr1 cells. Neuropeptide vasoactive intest-
inal peptide is released during inflammatory/autoim-
mune conditions, which induces generation of DCs with
a capacity to produce IL-10 and an inability to undergo
complete maturation, thereby driving generation of Tr1
cells [24]. Exposure of DCs to cyclo-oxygenaase-2 over-
expressing gliomas results in IL-10 production by DCs
which also drives Tr1 response, which may be depen-
dent on robust secretion of Prostaglandin E2 from the
glioma [25]. Additionally, bacterial peptides such as fila-
mentous hemagglutinin from Bortadella pertusis can
directly affect DCs by suppressing their ability to pro-
duce IL-12 and instead inducing production of IL-10,
which drives generation of Tr1 cells [26]. Individuals
infected with Plasmodium vivax have elevated levels of
Tr1 cells and culture of mononuclear cells from healthy
individuals with Plasmodium vivax extracts can drive
generation of Tr1 cells, indicating that certain peptides
produced from Plasmodium vivax may affect DC func-
tion which leads to Tr1 generation [27].
ICOSL signalling by DCs drives Tr1 differentiation
In addition to IL-10 production by pulmonary DCs,
ICOS-ICOSL signalling is also critical for Tr1 induction.
Pulmonary DCs upregulate ICOSL upon maturation
which is also critical for Tr1 induction since inhibition
of ICOSL on pulmonary DCs suppresses Tr1 induction
[28]. Plasmacytoid DCs also upregulate ICOS ligand
upon maturation, which has been shown to drive differ-
entiation of T cells into Tr1 cells [29].
TGF-b1 production by DCs drives Tr1 differentiation
TGF-b may also have a role in priming Tr1 differentia-
tion, since addition of neutralizing antibodies against
TGF-b to a coculture of CD4
-CD8
- splenic DCs and T
cells drastically reduces the production of IL-10 by T
cells [30]. CD4
-CD8
- spenic DC subsets secrete elevated
levels of TGF-b upon stimulation with lipopolysacchar-
ide (LPS) and subsequently prime differentiation of IL-
10 producing Tr1 cells [30].
Other DC driven signals which drive Tr1 differentiation
Along with TGF-b, CD40 signaling also plays a role in
the ability of CD4
-CD8
- DCs to prime Tr1 generation,
since CD40 ligation abrogates the ability of CD4
-CD8
-
DCs to prime Tr1 cells [31]. Furthermore, TLR9 stimu-
lation via CpG DNA and TLR4 stimulation via LPS can
convert these Tr1 inducing DCs into Th1 and Th1/
Th17 inducing DCs respectively [23]. Mature pDCs iso-
lated from peripheral blood of rheumatoid arthritis
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ase, which has also been implicated in promoting differ-
entiation of T cells into Tr1 phenotype [32].
Foxp3
+ Regulatory T cells
Foxp3
+ regulatory T cells (Foxp3
+ Tregs) are critical for
maintaining immune tolerance and preventing autoim-
mune reactions [33]. Foxp3
+ Tregs are identified by
their expression of CD25 (IL-2 receptor) and Foxp3, a
transcription factor critical for Treg differentiation [34].
Foxp3
+ Treg population can be divided into the natu-
rally occurring Foxp3
+ Treg population (nTreg), gener-
ally found in the thymus and the inducible Treg
population (iTreg), which is derived in the peripheral
tissues from CD4
+CD25
- precursors upon activation in
presence of TGF-b [35]. DCs are critical for Treg induc-
tion and in this section we offer an insight in the recent
advances in our understanding of how DCs can drive
nTreg and iTreg differentiation.
Naturally occurring Foxp3
+ Tregs
Natural Foxp3
+ Tregs (nTregs) comprise a distinct line-
age pathway determined at the double positive (CD4
+CD8
+) stage of thymocyte development due in part to
co-stimulatory signals initiating Foxp3 expression.
nTregs develop in the thymus during thymic develop-
ment upon recognition of self antigens. Although the
role of DCs in thymic selection is documented, the role
of DCs in generation of nTregs is highly controversial
[36]. Several studies have shown that DCs are dispensa-
ble for nTreg generation, whereby antigens specifically
expressed in thymic epithelial cells are sufficient to drive
differentiation of nTregs [37]. Conversely, there are stu-
dies identifying contribution of thymic DCs to genera-
tion of nTregs [38]. Thymic DCs include two
conventional DC subsets, which are CD8
loSirpa
hi/+ and
CD8
hiSirpa
lo/-,a m o n gw h i c hC D 8
loSirpa
hi/+ DCs have
been shown to play a role in inducing nTreg generation
in addition to their role in negative selection [39].
TSLP drives thymic DC mediated nTreg differentiation
Epithelial cells in Hassall’sc o r p u s c l e si nt h et h y m u s
produce thymic stromal lymphopoetin (TSLP) which
acts on thymic DCs by binding to TSLPR and IL-7R
alpha complex and drives induction of CD80, CD86
[38]. These DCs subsequently prime differentiation of
CD4
+CD8
-CD25
- thymocytes into nTregs, which is
dependent on IL-2 and CD28 signaling [40]. Therefore,
TSLP activated myeloid DCs in the thymus are likely
critical for positive selection of medium to high affinity
self reactive thymocytes to develop into nTregs [38]. In
addition to myeloid DCs, plasmacytoid DCs (pDCs)
residing in the thymus can also induce differentiation of
CD69
hiTCR
hiCD4
+CD8
+ thymocytes into nTregs and
this is dependent on CD40L crosstalk [41]. Thymic
pDCs also express TSLP receptor along with IL-7 recep-
tor complex and become responsive to TSLP produced
by thymic epithelial cells of Hassall’s corpuscles. TSLP
activated pDCs can then drive differentiation of nTregs
from CD4
+CD8
-CD25
- thymocytes, which can be inhib-
ited by Th1 and Th2 polarizing chemokines IL-12 and
IL-4 respectively [42].
T h er o l eo fT G F - b in driving nTreg differentiation is
highly controversial. Previous studies have shown nor-
mal nTreg numbers in TGFb-R1 deficient mice [35].
However, recently it has been shown that mice with
TGFb-R1 deletion have nTreg deficiency between post-
natal day 3 and 5, but subsequently there is a surge in
nTreg generation due to increased responsiveness of the
cells to IL-2 [43]. It remains to be investigated whether
thymic DCs produce TGF-b1 which can affect nTreg
generation.
Inducible Foxp3
+ Regulatory T cells
Inducible Foxp3
+ regulatory T cells (iTregs) are gener-
ated in the periphery by DCs and their generation
appears to be dependent on IDO, retinoic acid, Vitamin
Da n dT G F - b. iTregs cells play essential roles in
immune tolerance and in the control of severe chronic
allergic inflammation [44]. Furthermore, since iTregs are
induced in the periphery, they also act as barriers in
preventing the clearance of microorganisms and tumors,
whereby both are known to generate conditions that can
drive iTreg differentiation [45,46]. Figure 2 provides an
overview of the pathways involved in DC mediated
iTreg differentiation.
Indoleamine 2,3-dioxygenase in DCs drives iTreg
differentiation
DC populations expressing indoleamine 2,3-dioxygenase
(IDO) can play a critical role in immune tolerance by
promoting iTreg induction [47]. IDO catalyzes trypto-
phan metabolism via the kynurenine pathway and there-
fore depletes the local environment of tryptophan.
Tryptophan catabolism likely plays an important role in
suppressing T cell proliferation by arresting T cells in
G1 phase of cell cycle [48]. However, recent studies
have highlighted an important role of tryptophan cata-
bolites in mediating iTreg induction by exerting their
effects directly on DCs. During HIV infection, IDO
activity is critical in regulating Treg/Th17 balance with
increased IDO levels produced by DCs, associated with
a chronic inflammatory state in progressive HIV disease
due to a breakdown of mucosal barrier [49]. Certain DC
subsets such as pDCs, certain splenic DCs populations
such as CD19
+ DCs and nasal DCs have been identified
to upregulate IDO upon stimulation [50]. Induction of
IDO in DCs appears to be dependent on aryl
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Page 4 of 10hydrocarbon receptor (AhR), for DCs lacking Ahr fail to
upregulate IDO and prime T cell response instead of
tolerance induction [51]. Activation of Ahr in mice by
2,3,7,8-Tetrachlorodibenzo-p-dioxin(TCDD), commonly
referred to as dioxin, for 10 days, results in IDO induc-
tion both in the lungs and spleen along with upregula-
tion of Foxp3 in the spleen, which could be suppressed
by inhibiting IDO [52].
DCs residing in the nasal lymph nodes play an impor-
tant role in inducing tolerance to inhaled antigens. Stu-
dies have identified selective induction of IDO in non-
plasmacytoid DCs in the nasal lymph nodes, which is
critical for inducing tolerance, for abrogation of IDO
induction results in elimination of tolerance induction
towards the inhaled antigen [53]. In a murine model of
experimental autoimmune encephalitis, IDO deficient
mice show exacerbation of encephalitis, which can be
inhibited by treatment with tryptophan metabolite 3-
hydroxyanthranilate (3-HAA), generated during IDO
mediated tryptophan catabolism. Treatment with 3-
HAA drives TGF-b production from DCs and also sup-
presses IL-6 production, which ends up driving iTreg
induction [54]. Kynurenine, the first metabolite of IDO
driven tryptophan metabolism activates the AhR on T
cells, thereby driving iTreg differentiation [55]. TLR9
ligation drives induction of IDO in pDCs which sup-
presses IL-6 production, suppressing conversion of naive
T cells into Th17 cells and instead promoting iTreg
induction [56]. IDO driven kynurenine generation also
appears to be important for pDC mediated iTreg differ-
entiation [57]. Human monocyte derived DCs, cultured
under low tryptophan conditions, selectively upregulate
inhibitory receptors ILT3 and ILT4 and drive iTreg
induction [58].
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Figure 2 DCs drive differentiation of foxp3
+ inducible regulatory T cells. (iTregs). DCs secrete TGF-b, which induces foxp3 in naive T cells,
driving differentiation of naive T cells into iTregs. Activation of AhR and TLR9 drives induction of IDO, which catalyzes tryptophan metabolism.
Tryptophan metabolites promote iTreg generation through induction of TGF-b production and suppression of Th17 inducing cytokine, IL-6.
Furthermore, uptake of apoptotic DCs by viable DCs along with exposure to haptens, glucocorticoids and UV radiation also induces TGF-b
production, which drives iTreg differentiation. Other signals such as RANK/RANKL signalling by vitamin D treated keratinocytes and treatment of
DCs with vasoactive intestinal peptide (VIP), hepatocyte growth factor (HGF) and prostaglandin-D2 (PGD2) also promote iTreg differentiation.
Moreover, retinoic acid promotes iTreg differentiation by suppressing cytokines which are inhibitory to iTreg differentiation and targeting of
antigen to DEC205 drives iTreg differentiation through a TGF-b dependent mechanism.
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Skin DCs include langerhans cells (LCs) and dermal
DCs, with LCs being frequently associated in mainte-
nance of immune tolerance for acute depletion of LCs
has been associated with an enhancement of dermal
immune response [59]. Patients with langerhans cell his-
tiocytosis, a condition with uncontrolled proliferation of
LCs, show expansion of Foxp3
+ Treg populations, indi-
c a t i n gar o l eo fL C si nF o x p 3
+ Treg expansion [60].
Exposure of UVR-exposed skin to haptens results in
induction of iTregs, which is not observed upon LC
depletion, supporting the role of LCs in inducing iTregs
and suppressing immune reaction in the skin [61]. Mice
with LC specific TGF-b depletion, show signs of auto-
immune disease in the skin and fail to develop LCs,
indicating a role for LC derived TGF-b in LC develop-
ment and also pointing towards a role of LC in mainte-
nance of immune tolerance [62]. TGF-b production by
LCs could in fact be a potential mechanism of how LCs
can prime differentiation of Tregs. In nickel allergy
patients, administration of oral glucocorticoids leads to
TGF-b production by LCs, which expands iTregs and
results in reduction of clinical symptoms [63].
CD8a
+ DCs were initially identified in the mouse
spleen with a propensity to drive iTreg induction [64].
Au n i q u eC D 8
+ splenic DC subset, which expresses
DEC205, a type I transmembrane protein with multiple
C-type lectin domains, has been identified in the mouse
spleen, and preferentially drives differentiation of iTregs
[65]. CD8
+DEC205
+ DCs can drive iTreg differentiation
both in vitro and in vivo in presence of low dose of the
antigen without addition of any exogenous TGF-b.
However, iTreg induction mediated by CD8
+DEC205
+
DCs is dependent on TGF-b for addition of TGF-b neu-
tralizing antibody suppresses iTreg differentiation [65].
Furthermore, Polyinosinic:polycytidylic acid (poly I:C)
induced maturation of CD8
+DEC205
+ DCs reduces their
ability to drive iTregs, pointing towards their role in
maintaining peripheral tolerance under steady state con-
ditions. Targeting of small amounts of antigen to DCs
by using antigen fused to DEC205 antibody under con-
ditions of suboptimal DC activation has been shown to
drive iTreg induction [66]. Another CD8
- splenic subset,
which expresses DCIR-2, a type II transmenbrane pro-
tein with a single external C-type lectin domain, drives
iTreg differentiation when exogenous TGF-b is added.
However, in absence of exogenous TGF-b,C D 8
- splenic
DCs are better at stimulating nTregs rather than driving
iTreg differentiation [65].
Pulmonary DCs mediate inhalational tolerance which
occurs during non-inflammatory settings through CCR7
dependent migration of pulmonary DCs to the draining
bronchial lymph node [67]. In the absence of inflamma-
tory signal, pulmonary DCs acquire antigens and
subsequently acquire a semi mature phenotype charac-
terized by intermediate expression of costimulatory
molecules and high levels of MHC II expression, fol-
lowed by subsequent migration to bronchial lymph
nodes, where tolerance is induced [68]. Additionally,
local microenvironment in the lung also plays a role in
driving iTregs. Pulmonary stromal cells can produce
cytokines such as TGF-b which can drive differentiation
of pulmonary DC into IL-10 and TGF-b producing DCs
which can subsequently drive iTreg differentiation [69].
Uptake of apoptotic DCs by viable DCs suppresses DC
maturation and instead induces production of TGF-b1 via
the mTOR signalling pathway [70-72]. TGF-b1 producing
DCs subsequently interact with naive T cells and drive
Foxp3 induction, thereby driving iTreg differentiation.
RANKL signalling on DCs drives iTreg differentiation
Local environment within skin could also contribute
towards maintenance of tolerance by DCs. The interplay
between vitamin D and RANKL-RANK signalling in the
skin plays a role in inducing an environment which pro-
motes DC induced iTreg induction. The activated meta-
bolite of vitamin D (1,25-dihydroxyvitamin D3,V D 3)
exerts actions through its nuclear receptor, the VD3
receptor (VDR) [73]. VDR is expressed on immune cells
such as DCs and Vitamin D treatment of DC inhibits
maturation along with their ability to prime alloreactive
T cell response [74]. Keratinocytes in the inflamed skin
over express RANKL, which through RANKL-RANK
signalling modulates the function of DCs in the epider-
mis to expand iTregs [75]. Application of topical vita-
min D analog, calcipotriol, followed by transcutaneous
immunization with a protein agent results in induction
of iTregs, primarily due to induction of RANKL on ker-
atinocytes which likely modulates DC function to drive
iTreg differentiation [76]. iTreg induction upon topical
application of vitamin D is absent in mice lacking vita-
min D receptor, indicating vitamin D driven RANKL as
the likely mechanism of how vitamin D can mediate
skin tolerance by inducing iTregs [76].
Retinoic acid producing DCs drive iTreg differentiation
Oral intake of protein antigens leads to induction of oral
tolerance, which is largely mediated through generation
of iTregs in the mesenteric lymph nodes. DCs in the
mesenteric lymph nodes express cyclooxygenase-2 (cox-
2), which plays a role in iTreg induction. Suppression of
cox-2 in mesenteric DCs results in induction of GATA-
3 along with IL-4 in T cells and suppresses iTreg induc-
tion [77]. In addition to cox-2, mesenteric DCs express
high levels of B7-H1 and B7-DC, which are B7 family
costimulatory molecules and are also essential for
mesenteric DC driven induction of iTregs [78]. The
most well studied mechanism of how oral tolerance
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(RA) is an active metabolite of vitamin A which regu-
lates multiple cellular processes such as cell death, pro-
liferation and differentiation through the retinoic acid
receptors (RAR, including a, b and g subtypes) and the
retinoic × receptors (RXR, also including a, b and g sub-
types). RA has been shown to suppress inflammatory
responses in animal models of multiple diseases such as
inflammatory bowel disease and experimental autoim-
mune encephomyelitis. A unique population of DCs,
characterized by the expression of alpha E integrin,
CD103 has been identified in the gut associated lym-
phoid tissue (GALT) as well as in the mesentereic
lymph node with a specialized function of inducing
Tregs and maintaining immune tolerance [79,80].
CD103
+ DCs selectively drive iTreg differentiation
through RA and TGF-b dependent process, since addi-
tion of inhibitors of RA production or TGF-b neutraliz-
ing antibody suppresses iTreg induction [79,80]. CD103
+ DC derived RA also drives induction of a4b7 integrin
and CCR9 on newly generated iTregs, which makes
them home to GALT [81]. Furthermore, RA also sus-
tains stability and function of iTregs, even under inflam-
matory setting which further results in tolerance
induction [82]. The mechanism of how RA can drive
iTreg induction is not completely understood. Initially,
RA was thought to inhibit effects of IL-6 signaling,
which promoted iTreg induction rather than induction
of Th17 in presence of TGF-b [83]. Later studies indi-
c a t e dt h a tR As u p p r e s s e st h eg e n e r a t i o no fC D 4 4
hi
effector memory T cells, which secrete IL-4, IL-21 and
IFN-g, and suppress TGF-b mediated iTreg differentia-
tion [84]. However, RA can also interfere with the
effects of inhibitory cytokines on iTreg differentiation
and can promote iTreg induction in absence of inhibi-
tory cytokines, which is dependent on RAR-a [85].
Immune deficient mice lacking CD103 fail to suppress
T cell mediated colitis upon transfer of Tregs, pointing
towards a role of CD103
+ DCs in maintaining intestinal
immune homoestasis [86]. Curcumin treatment of bone
marrow derived DCs drives expression of Aldh1a, an
enzyme involved in RA production, which makes DCs
behave similarly to mucosal CD103
+ DCs and drive RA
mediated induction of iTregs [87]. The local intestinal
environment also modulates DC function. Intestinal
epithelial cells produce TGF-b, retinoic acid which drive
a tolerogenic DC phenotype, which can then subse-
quently drive iTreg differentiation [88,89]. Additionally,
lamina propria macrophages also suppress intestinal DC
induced Th17 response, which could inadvertently
prime iTreg differentiation [90].
CD103
-CD11b
+ DC subset has been identified in the
skin and expresses 3 aldehyde dehydrogenases, which
catalyze conversion of retinal to RA, giving this subset
the unique property of priming iTreg differentiation
[91]. Furthermore, treatment of mice with AhR ligand
2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid
methyl ester (ITE) has been shown to result in genera-
tion of tolerogenic DCs which promote iTreg differen-
tiation through a RA dependent mechanism [92].
Other DC derived signals which drive iTreg differentiation
Mast cell derived Prostaglandin-D2 (PGD2) is a media-
tor of inflammation which promotes infiltration of eosi-
nophils and Th2 cells into the lung during asthma.
PGD2 can act through DP1 or DP2 receptor. Studies
have shown that treatment of asthmatic mice with DP1
agonist can in fact suppress features of asthma by acting
on pulmonary DCs and inducing cAMP dependent pro-
tein kinase A activation, which suppresses the ability of
DCs to drive Th2 response and instead promotes induc-
tion of iTregs [93].
Additionally, treatment of DCs with immunosuppres-
sive peptides has also been shown to drive iTreg differen-
tiation. DCs treated with immunosuppressive
neuropeptide, vasoactive intestinal peptide (VIP) drive
iTreg differentiation, which is likely mediated by the abil-
ity of VIP to suppress DC maturation and proinflamma-
tory cytokine production [94,95]. Moreover, DCs upon
treatment with hepatocyte growth factor (HGF) also
drive iTreg differentiation, which is abrogated if DCs are
treated with antibodies against HGF receptor [96]. How-
ever, the mechanisms of how HGF receptor signalling in
DC drives iTreg differentiation is not understood.
Th3 cells
Th3 cells were first identified as a novel population of T
cells induced upon induction of peripheral tolerance
upon oral delivery of myelin basic protein, which sup-
pressed experimental autoimmune encephalitis in mice
[97]. These Th3 cells are class II-restricted T cells with
identical ab TCR as Th1 and Th2 cells. Moreover, they
are characterized by production of high levels of TGF-b
along with low amounts of IL-4 and IL-10 with no pro-
duction of IFN-g or IL-2. The ability of these cells to
suppresses EAE is largely TGF-b dependent. Secretion
of TGF-b by Th3 cells drives induction of Foxp3 in acti-
vated T cells, driving them towards iTreg phenotype
[98]. Furthermore, Foxp3 can also be induced in Th3
cells for studies have shown that transient induction of
TGF-b1 in T cells during activation in absence of IL-2
can drive generation of Foxp3
+ Th3 cells which com-
prise a distinct Treg phenotype, which is CD25
- and can
control hyperproliferative T cell response [99].
Double negative regulatory T cells
TCR
+CD3
+CD4
-CD8
- double negative (DN) regulatory
T cells inhibit immune response by Fas/FasL destruction
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Although, the mechanisms of how DCs can prime dif-
ferentiation of DN Tregs is not understood, syngeneic
DCs have been successfully utilized for expansion of
antigen specific DN Tregs [101].
Conclusion
DCs play a critical role in the induction of tolerance.
One of the active mechanisms whereby DCs induce/
maintain tolerance is through induction of Tregs. Over
the last decade, significant progress has been made in
understanding the DC specific signals that can drive
induction of Tregs. These findings can potentially be
employed to generate tolerogenic DCs which can be
used for tolerance induction in hypersensitivity, autoim-
munity as well as transplantation.
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